Gujarat Kidney Super Speciality Ltd vs Healthcare Global Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 176.95 as of 23 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Healthcare Global Enterprises Ltd changed from 69.7 on March 2022 to 570.3 on March 2026 . This represents a CAGR of 52.26% over 5 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Healthcare Global Enterprises Ltd changed from ₹ 2394 crore on March 2021 to ₹ 7833 crore on March 2026 . This represents a CAGR of 21.84% over 6 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Healthcare Global Enterprises Ltd for the Jun '26 is ₹ 708.16 crore as compare to the Mar '26 revenue of ₹ 665.92 crore. This represent the growth of 6.34% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Healthcare Global Enterprises Ltd for the Jun '26 is ₹ 135.32 crore as compare to the Mar '26 ebitda of ₹ 106.76 crore. This represent the growth of 26.75% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 9 quarters. This represents a CAGR of 29.77% The net profit of Healthcare Global Enterprises Ltd changed from ₹ 13.63 crore to ₹ 16.46 crore over 9 quarters. This represents a CAGR of 8.75% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Healthcare Global Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises Limited was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a Private Limited Company.
The name of the Company was changed to HealthCare Global Enterprises Private Limited on November 14, 2005.
Thereafter, it was converted into a Public Limited Company and the name of the Company was changed to Healthcare Global Enterprises Limited on July 5, 2006. Presently, the Company is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.
Under the 'HCG' brand, the Company operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Healthcare Global Enterprises Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Healthcare Global Enterprises Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,395 Cr while Market cap of Healthcare Global Enterprises Ltd is 8,213 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Healthcare Global Enterprises Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Healthcare Global Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Healthcare Global Enterprises Ltd?

As of October 25, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹176.95. On the other hand, Healthcare Global Enterprises Ltd stock price is INR ₹550.15.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Healthcare Global Enterprises Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Healthcare Global Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.